COMP <GO>
RPRX vs TEVA // EV/EBITDA & P/E VALUATION
Royalty Pharma plc (Class A) (NASDAQ) VS. Teva Pharmaceutical Industries Limited (NYSE) • 15-METRIC TALLY: RPRX 6
— TEVA 5
▲ EV/EBITDA & P/E VALUATION LEADER: TEVA
LAST: $67.18 (+1.90%) • MKT CAP: $37.91B
valuation
27.8x
LAST: $42.09 (+1.50%) • MKT CAP: $48.32B
valuation
20.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RPRX VS. TEVA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RPRX | TEVA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 51.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.00% | 9.40% | -2.40 | TEVA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 27.8x | 20.8x | +7.00 | TEVA | /valuation <GO> |
| Free Cash Flow Yield | 6.29% | 1.81% | +4.48 | RPRX | /fcf-yield <GO> |
| Operating Margin | 65.60% | 12.50% | +53.10 | RPRX | /operating-margins <GO> |
| Net Profit Margin | 32.40% | 8.20% | +24.20 | RPRX | /net-margins <GO> |
| Revenue Growth (YoY) | 5.10% | 4.30% | +0.80 | RPRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.90 | 1.02 | +1.88 | RPRX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.6 | 58.6 | +10.00 | RPRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 1.00 | -0.06 | TEVA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 45.8x | 31.9x | +13.90 | TEVA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $37.91B | $48.32B | -$10.41B | TEVA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RPRX REV | TEVA REV | RPRX GROSS % | TEVA GROSS % | RPRX FCF | TEVA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.38B | $17.26B | — | 51.8% | $2.38B | $872.4M |
| FY 2024 | $2.26B | $16.54B | — | 48.7% | $2.67B | $502.5M |
| FY 2023 | $2.35B | $15.85B | — | — | $2.88B | $654.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RPRX // BETA 0.94
TEVA // BETA 1.00